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The in vivo pathways involved in generating antigenspecific donor T cell responses that can deliver GVL effects after BMT are unclear. We have developed a novel model of AML relapse following T cell depleted allograft, in order to study the role of leukemia-specific antigen in generating protective alloresponses following donor lymphocyte infusion. We hypothesized that, as the most potent of the professional antigen presenting cells (APC), conventional dendritic cells (cDC) could make a significant contribution to the cross-presentation of low-abundance leukemia-specific antigen and the downstream development of robust leukemia-specific cytolytic T cell responses.
In the first instance, we assessed the capacity of cDC to cross-present both a leukemia-restricted and an ubiquitous model alloantigen using a novel system (schematic shown in Fig. 1a ). We undertook primary transplants using T cell depleted bone marrow from B6.CD11c.GCDL donors (in which eGFP, Cre, the diphtheria toxin receptor and luciferase are driven off the CD11c promotor) and Bm1 or Bm1.ActmOVA class I mismatched recipients. The reconstituted mice have B6-derived hematopoiesis and Bm1-derived parenchyma (Table 1) .
We used ovalbumin (OVA) as a model alloantigen and transferred leukemic cells from Bm1.ActmOVA mice, 6 weeks after primary transplant when donor engraftment was complete. The presentation of SIINFEKL, the dominant OVA-derived peptide presented in class I, was measured by the proliferative response of CD8 + OT-I transgenic T cells.
These T cells can only respond to B6-derived MHC class I presenting the SIINFEKL peptide. In this system, this means that any antigen presentation will be from engrafted hematopoietic cells (derived from the B6 donor marrow that has reconstituted in the chimeric mice) that are crosspresenting ovalbumin derived from leukemia only (when leukemia was transferred into [B6.CD11c.GCDL → Bm1]) or when ovalbumin could be derived from both parenchyma and leukemia ([B6.CD11c.GCDL → Bm1.ActmOVA]).
To confirm we could adequately deplete DC, hence measure the T cell responses in their presence and absence, we used bioluminescent imaging to assess DC maintenance and deletion in the B6.CD11cGCDL → Bm1 chimeras and the B6.CD11cGCDL → Bm1.ActmOVA chimeras. As shown in Fig. 1b , DT treatment effectively depleted CD11c positive cells by day 0, as shown by marked reduction in bioluminescent signal. This is quantified in Fig. 1c .
Having transferred OVA-bearing leukemia, we next reirradiated the mice to model reinduction therapy, and transferred donor OT-I T cells to determine proliferation by violet proliferation dye dilution as a measure of antigen presentation. As shown in Fig. 2a , proliferation was most robust where cDC were present and alloantigen was ubiquitous. In the presence of ubiquitous antigen, leukemiaderived antigen did not contribute to antigen presentation above the non-leukemic control (Fig. 2b ). In the case where only leukemia-derived antigen was present, DC were required for its cross-presentation and indeed, in the absence of DC there was no difference between OT-I accumulation when compared with the non-leukemia (i.e., no antigen) controls (red bars). This suggests that where a low-abundance, leukemia-specific antigen is present, reconstituted donor DC are critical for cross-presentation of this antigen to antigen-specific donor T cells, and can lead to a net stimulatory response rather than the deletion that occurs when recipient DC present highly abundant endogenous antigens [1] .
With regard to graft-versus-host (GVH) effects, it is increasingly clear that recipient-type cDC play a largely regulatory role rather than a stimulatory one (now that non-hematopoietic antigen presentation contributes to the initiation of MHC class II-dependent GVHD [1] [2] [3] [4] . Donor APC influence the severity of GVHD, but are inefficient at initiating disease in isolation, and make minimal contribution to GVL in systems that utilize various cell lines [5, 6] .
Using our novel model of post-allograft relapse, we conclude that cross-presentation of leukemia-restricted antigen by cDC is likely to be important for the generation of leukemia-specific T cell responses after BMT, and may be especially important in the setting of relapsed disease. Since leukemia and/or hematopoietic-specific antigens are increasingly being identified [7] ) and Bm1.ActmOVA (H-2K bm1 and ubiquitous ovalbumin expression driven off the betaactin promotor) [12] were used in the study. Female mice between 6 and 12 weeks of age were used throughout. To generate chimeras, Bm1 or Bm1.ActmOVA mice were irradiated (1000 cGy, total body irradiation; TBI) and transplanted with 5 × 10 6 B6.CD11c.GCDL T cell depleted (TCD) bone marrow (BM). To overcome the MHC class I mismatch and prevent GVHD developing in the chimeric mice, CD8α-depleting antibody was administered via intravenous (IV) injection on d0 (1 mg, produced in-house). Mice were allowed to reconstitute for 6 weeks prior to the transfer of leukemic cells. (ii) Primary leukemia cells were generated as previously described [13] and cryopreserved at disease onset, for subsequent transplantation. Leukemia cells were thawed on the day of injection and included in grafts at 0.5-1 × 10 6 per mouse. (iii) Two weeks following leukemia injection, mice were pre-treated with DT or saline, irradiated and OT-I T cells labelled with violet proliferation dye (VPD) were transferred to measure antigen presentation. OT-I Tg T cells were MACS-purified from spleen and LN on the basis of CD8-expression (Miltenyi Biotec). For violet proliferation dye labelling, OT-I were incubated prior to transfer according to the manufacturer's directions (BD Biosciences). For in vivo depletion of DTR expressing DC, diphtheria toxin from Corynebacterium diphtheriae (Sigma Aldrich, St Louis, MO) was administered intraperitoneally at 160 ng per dose on day −2, −1, 0, 1, 2. b Chimeric mice were treated with saline (DC intact) or DT (DC depleted), and resulting DC depletion demonstrated by bioluminescence imaging (BLI); representative images shown. Recipients were injected subcutaneously with D-Luciferin (0.5 mg, PerkinElmer) and then anesthetized with isoflurane 5 min before imaging using the Xenogen imaging system (Xenogen IVIS 100; Caliper Life Sciences) as we have previously described [14] . As the reconstituted cDC express luciferase driven off the CD11c promoter, the BLI signal is representative of total body cDC. Representative images from one of two replicate experiments is shown. c Quantification of bioluminescent signals in the DT-treated, cDC depleted mice. Bioluminescence (BLI) is presented as photons per second (ph/s) 
